• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

INDINAVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • INDINAVIR chembl:CHEMBL115 Approved

    Alternate Names:

    CRIXIVAN
    L-735524
    INDINAVIR
    INDINAVIR SYSTEM SUITABILITY
    INDINAVIR MONOHYDRATE
    MK-639
    INDINAVIR ANHYDROUS
    (1(1S,2R),5(S))-2,3,5-TRIDEOXY-N-(2,3-DIHYDRO-2-HYDROXY-1H-INDEN-1-YL)-5-(2-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)-4-(3-PYRIDINYLMETHYL)-1-PIPERAZINYL)-2-(PHENYLMETHYL)-D-ERYTHRO-PENTONAMIDE
    chemidplus:150378-17-9
    pubchem.compound:5362440
    rxcui:1546024
    rxcui:114289
    chembl:CHEMBL115
    drugbank:00224

    Drug Info:

    (1 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Skowron et al., 1999, The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial., J. Infect. Dis.
    Lenhard et al., 2000, HIV protease inhibitors block adipogenesis and increase lipolysis in vitro., Antiviral Res.
    Maruo Y et al., 1999, Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism., Pediatrics
    Akaba K et al., 1998, Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese., Biochem Mol Biol Int
    Yamamoto K et al., 1998, Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II., Biochim Biophys Acta
    Bosma PJ et al., 1995, The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome., N Engl J Med
    Turatti L et al., 2012, Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil., AIDS Res Hum Retroviruses
    Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk., Clin Cancer Res
    Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
    Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis., Eur J Cancer
    Onoue M et al., 2009, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients., Int J Clin Oncol
    Takano M et al., 2009, Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study., Oncology
    Hoskins JM et al., 2007, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters., J Natl Cancer Inst
    Jada SR et al., 2007, Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients., Cancer Sci
    Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
    Urawa N et al., 2006, Linkage disequilibrium of UGT1A1 *6 and UGT1A1 *28 in relation to UGT1A6 and UGT1A7 polymorphisms., Oncol Rep
    Toffoli G et al., 2006, The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer., J Clin Oncol
    Boyd MA et al., 2006, Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir., Pharmacogenet Genomics
    Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
    Rotger M et al., 2005, Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia., J Infect Dis
    Zhang D et al., 2005, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation., Drug Metab Dispos
    Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
    Rouits E et al., 2004, Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients., Clin Cancer Res
    Innocenti F et al., 2004, Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan., J Clin Oncol
    Tukey RH et al., 2002, Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity., Mol Pharmacol
    Ando Y et al., 2000, Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis., Cancer Res
    Hall D et al., 1999, Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates., Pharmacogenetics
    Hruz et al., 2002, Indinavir induces acute and reversible peripheral insulin resistance in rats., Diabetes
  • INDINAVIR   UGT1A1

    Interaction Score: 4.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539


    Sources:
    PharmGKB

  • INDINAVIR   TFAP2A

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10996400


    Sources:
    NCI

  • INDINAVIR   CSF2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10479132


    Sources:
    NCI

  • INDINAVIR   SLC2A4

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11916910


    Sources:
    NCI

  • INDINAVIR   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • INDINAVIR   CYP3A4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528 22931300


    Sources:
    DTC PharmGKB

  • INDINAVIR   CYP2C19

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • INDINAVIR   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • INDINAVIR   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • INDINAVIR   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NCI: INDINAVIR

    • Version: 14-September-2017

    Alternate Names:
    C1662 NCI drug code

    Drug Info:

    Publications:
    Lenhard et al., 2000, HIV protease inhibitors block adipogenesis and increase lipolysis in vitro., Antiviral Res.
    Hruz et al., 2002, Indinavir induces acute and reversible peripheral insulin resistance in rats., Diabetes
    Skowron et al., 1999, The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial., J. Infect. Dis.

  • DTC: INDINAVIR

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL115 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: indinavir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Maruo Y et al., 1999, Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism., Pediatrics
    Bosma PJ et al., 1995, The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome., N Engl J Med
    Jada SR et al., 2007, Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients., Cancer Sci

  • TTD: Indinavir

    • Version: 2020.06.01

    Alternate Names:
    D0V7CF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL115

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21